GABAA receptor positive allosteric modulators modify the abuse-related behavioral and neurochemical effects of methamphetamine in rhesus monkeys.
Abstract
GABAA receptor positive allosteric modulators (GABAA receptor modulators) are commonly used for the treatment of insomnia. Nevertheless, the effects of these compounds on psychostimulant-induced sleep impairment are poorly understood. Because GABAA receptor modulators have been shown to decrease the abuse-related effects of psychostimulants, the aim of the present study was to evaluate the effects of temazepam (0.3, 1.0 or 3.0 mg/kg) and eszopiclone (0.3, 1.0 or 3.0 mg/kg), two GABAA receptor modulators, on the behavioral neuropharmacology of methamphetamine in adult rhesus macaques (n = 5). S...
Source: Neuropharmacology - May 8, 2017 Category: Drugs & Pharmacology Authors: Berro LF, Andersen ML, Tufik S, Howell LL Tags: Neuropharmacology Source Type: research
Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem ‐containing medications
ConclusionThe DSCs related to zolpidem‐containing products shifted prescribing toward the lower‐dose formulations, consistent with the recommendations in the DSCs. Copyright © 2017 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - April 27, 2017 Category: Drugs & Pharmacology Authors: Aaron S. Kesselheim, Macarius Donneyong, Gerald J. Dal Pan, Esther H. Zhou, Jerry Avorn, Sebastian Schneeweiss, John D. Seeger Tags: Original Report Source Type: research
The dual orexin receptor antagonist, DORA ‐22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine
This article is protected by copyright. All rights reserved. (Source: Journal of Neurochemistry)
Source: Journal of Neurochemistry - April 26, 2017 Category: Neuroscience Authors: Lihang (Leon) Yao, Andres Ramirez, Anthony J. Roecker, Steven Fox, Jason Uslaner, Sean M. Smith, Robert Hodgson, Paul J. Coleman, John J. Renger, Christopher J. Winrow, Anthony L. Gotter Tags: Original Article Source Type: research
Response to a combination of oxygen and a hypnotic as treatment for obstructive sleep apnoea is predicted by a patient's therapeutic CPAP requirement
ConclusionTherapeutic CPAP requirement, as a surrogate measure of pharyngeal collapsibility, predicts the response to non‐anatomical therapy (oxygen and eszopiclone) for OSA. (Source: Respirology)
Source: Respirology - April 14, 2017 Category: Respiratory Medicine Authors: Shane A. Landry, Simon A. Joosten, Scott A. Sands, David P. White, Atul Malhotra, Andrew Wellman, Garun S. Hamilton, Bradley A. Edwards Tags: Original Article Source Type: research
Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment
ConclusionThere is generally poor evidence for prescribing drugs for behavioural insomnia in children with ADHD. Further controlled studies are warranted. (Source: Pediatric Drugs)
Source: Pediatric Drugs - April 8, 2017 Category: Pediatrics Source Type: research
Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.
CONCLUSION: There is generally poor evidence for prescribing drugs for behavioural insomnia in children with ADHD. Further controlled studies are warranted.
PMID: 28391425 [PubMed - as supplied by publisher] (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 8, 2017 Category: Pediatrics Authors: Anand S, Tong H, Besag FM, Chan EW, Cortese S, Wong IC Tags: Paediatr Drugs Source Type: research
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study
ConclusionsSome risks of medications are effectively communicated to patients and physicians; however, there is still a noticeable gap between information issued by the Food and Drug Administration and patient and physician awareness of this knowledge, as well as patients ’ decisions to act on this information. Disseminators of emerging drug safety information should explore ways of providing user-friendly resources to patients and healthcare professionals that can update them on new risks in a timely manner. (Source: Drug Safety)
Source: Drug Safety - February 27, 2017 Category: Drugs & Pharmacology Source Type: research
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline
Introduction:The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of ...
Source: Journal of Clinical Sleep Medicine : JCSM - February 15, 2017 Category: Sleep Medicine Source Type: research
Eszopiclone and Zolpidem Do Not Affect the Prevalence of the Low Arousal Threshold Phenotype
Conclusions:The LAT is common in our population and NBSH premedication does not alter its occurrence. Further studies are needed to determine how the LAT can be optimally managed to improve OSA treatment.Citation:Smith PR, Sheikh KL, Costan-Toth C, Forsthoefel D, Bridges E, Andrada TF, Holley AB. Eszopiclone and zolpidem do not affect the prevalence of the low arousal threshold phenotype.J Clin Sleep Med. 2017;13(1):115–119. (Source: Journal of Clinical Sleep Medicine : JCSM)
Source: Journal of Clinical Sleep Medicine : JCSM - January 14, 2017 Category: Sleep Medicine Source Type: research
An update of management of insomnia in patients with chronic orofacial pain
This article is protected by copyright. All rights reserved. (Source: Oral Diseases)
Source: Oral Diseases - December 31, 2016 Category: ENT & OMF Authors: Galit Almoznino, Yaron Haviv, Yair Sharav, Rafael Benoliel Tags: Review Article Source Type: research
The Combination of Supplemental Oxygen and a Hypnotic Markedly Improves Obstructive Sleep Apnea in Patients with a Mild to Moderate Upper Airway Collapsibility
Conclusions:The combination of lowering loop gain and raising the arousal threshold is an effective therapy in patients whose anatomy is not severely compromised. Our work demonstrates that combining therapies that target multiple traits can resolve OSA in selected individuals.Clinical Trial Registration:ClinicalTrials.gov, ID: NCT01633827Citation:Edwards BA, Sands SA, Owens RL, Eckert DJ, Landry S, White DP, Malhotra A, Wellman A. The combination of supplemental oxygen and a hypnotic markedly improves obstructive sleep apnea in patients with a mild to moderate upper airway collapsibility.SLEEP 2016;39(11):1973–1983. (Source: Sleep)
Source: Sleep - November 1, 2016 Category: Sleep Medicine Source Type: research
Editor ’ s Message: September –October 2016 Issue Highlights
Dear Colleagues:
Welcome to the September-October 2016 issue of Innovations in Clinical Neuroscience (ICNS). As the official journal of the CNS Summit, the International Society for CNS Drug Development (ISCDD), and the International Society for CNS Clinical Trials and Methodology (ISCTM), an important part of our editorial mission is to accelerate and enhance of the development of cheaper, more effective treatments for our patients through technology, collaboration, and innovation—not just in neuroscience but in all disciplines of medicine and among all involved entities, including clinicians, researchers, and members o...
Source: Innovations in Clinical Neuroscience - October 9, 2016 Category: Neuroscience Authors: ICN Online Editor Tags: Current Issue Drug Development Editor's Message: Issue Highlights Neurology Psychiatry Trial Methodology Amir H. Kalali CNS Summit Innovations in Clinical Neuroscience ISCDD ISCTM Source Type: research
Eszopiclone-induced Parasomnia with Suicide Attempt: A Case Report
Conclusion
The possibility for adverse effects, including life-threatening events, when taking eszopiclone should be considered by all prescribers. The pharmacological profile of eszopiclone suggests a potential for a greater risk of adverse events than with other benzodiazepine-like hypnotics such as zolpidem, which has a one-percent risk for sleep-related amnestic behaviors.[10] This risk increases further with concomitant administration of monoaminergic drugs like SSRIs. The risk for these behaviors among patients taking eszopiclone is yet to be quantified and presents an opportunity for future research endeavors. Regar...
Source: Innovations in Clinical Neuroscience - October 9, 2016 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue Depression Mood Disorders Psychiatry Psychopharmacology Sleep Disorders benzodiazepine-like drug reaction Eszopiclone hypnotic insomnia parasomnia sedative Source Type: research
Nucleation behavior of eszopiclone-butyl acetate solutions from metastable zone widths
Publication date: 22 November 2016 Source:Chemical Engineering Science, Volume 155 Author(s): Shijie Xu, Jingkang Wang, Keke Zhang, Songgu Wu, Shiyuan Liu, Kangli Li, Bo Yu, Junbo Gong Experimental data on the critical supercooling ∆T max, a measure of metastable zone width (MSZWs), as a function of saturated temperature T 0 and cooling rate R were analyzed to describe the nucleation behavior of unseeded eszopiclone-butylacetate solutions. The Nývlt's semiempirical model and Sangwal's theory were employed, respectively. And moreover, we propose a modified model based on the Sangwal's theory in which the nuclea...
Source: Chemical Engineering Science - August 17, 2016 Category: Chemistry Source Type: research
New-Onset Visual Hallucinations With Eszopiclone.
Authors: McGuire JM, Duquette M, Burghart SM, Ferri MJ
PMID: 27486533 [PubMed - in process] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - August 5, 2016 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
